Adicet Bio Inc
ACET
$1.81
Closing
▼-3.47%
1D
▼-4.23%
YTD
Market cap
$148.73M
52 week high
$7.50
52 week low
$1.10
Volume
260,793
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$148.73M
Analysts' Rating
BUY
Price Target (Mean)
15.66667
Total Analysts
10
P/E
Operating Margin
0.00%
Beta
1.90
Revenue Growth (Annual)
156.83%
52 week high
$7.50
52 week low
$1.10
Div. Yield
%
EPS Annual Growth
54.67
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Adicet Bio, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. Its product candidate, ADI-001, is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 used for the treatment of relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Its pipeline also includes ADI-925, which is a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Its pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
